[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593784":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":70,"collaborators":10,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":83,"minAge":84,"maxAge":10,"enrollmentInfo":85,"targetDuration":88,"studyType":89,"phases":10,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Early-Stage Breast Cancer Patients Receiving Local Therapy",null,"This group includes people diagnosed with stage I to III breast cancer who are receiving local therapy with curative intent. Local therapy in this study includes surgery, as well as systemic treatments given before or after surgery, such as:\n\nNeoadjuvant therapy (for example, chemotherapy or targeted therapy given before surgery)\n\nAdjuvant therapy (for example, chemotherapy, radiotherapy, endocrine therapy, or targeted therapy given after surgery)\n\nThis is an observational study. There is no experimental intervention. All participants will undergo baseline assessments, including clinical evaluations, laboratory tests, patient-reported outcome questionnaires, and biospecimen collection. Participants will then be followed over time to monitor treatment-related toxicities and changes in quality of life.",[13],"Procedure: blood sampling",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","blood sampling","At baseline, participants will undergo peripheral blood collection using EDTA tubes. A total of 10 mL of venous blood will be collected and processed into plasma and peripheral blood mononuclear cells (PBMCs). Plasma samples will be stored at -80°C, and PBMCs will be cryopreserved in liquid nitrogen. These samples will be used for future biomarker discovery, multi-omics analysis, and studies of biological mechanisms underlying treatment-related toxicities.",[9],[21],{"name":22,"affiliation":23,"role":24},"Yi Fang, MD","National Cancer Center\u002FNational Clinical Research Center for Cancer\u002FCancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Zheng Qu, MD","CONTACT","+8615010998669","quzheng1237@gmail.com",[32,49,60],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"National Cancer Center\u002FCancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","RECRUITING","Beijing","Beijing Municipality","100021","China","CN",{"type":41,"coordinates":42},"Point",[43,44],116.39723,39.9075,{"lat":44,"lon":43},[47,48],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},{"name":22,"role":24,"phone":10,"phoneExt":10,"email":10},{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":38,"countryCode":39,"cosmosGeoPoint":55,"geoPoint":59,"contacts":10},"Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center","ACTIVE_NOT_RECRUITING","Shenzhen","Guangdong","518116",{"type":41,"coordinates":56},[57,58],114.0683,22.54554,{"lat":58,"lon":57},{"facility":61,"status":51,"city":62,"state":63,"zip":64,"country":38,"countryCode":39,"cosmosGeoPoint":65,"geoPoint":69,"contacts":10},"Shanxi Cancer Hospital","Taiyuan","Shanxi","030013",{"type":41,"coordinates":66},[67,68],112.56028,37.86944,{"lat":68,"lon":67},{"type":71,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","FangYi","Chief Physician and Professor","100593784","a-study-of-treatment-related-toxicities-and-quality-of-life-after-local-therapy-in-chinese-breast-cancer-patients-100593784",false,"NCT07010939","A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients","A Prospective Multi-modal Cohort Study of Local Treatment-related Toxicities and Quality of Life in Chinese Breast Cancer Patients (PERSEVERE)","PERSEVERE","Inclusion Criteria:\n\n* Women aged 18 years or older\n* Diagnosed with stage I, II, or III invasive breast cancer confirmed by pathology or cytology\n* No signs of metastatic disease (cancer that has spread to other parts of the body)\n* Scheduled to receive local treatment, including:\n\nSurgery\n\nAnd\u002For neoadjuvant or adjuvant therapy such as chemotherapy, radiation, hormone therapy, or targeted therapy\n\n* Willing and able to complete health questionnaires and attend follow-up visits\n* Has given written informed consent to join the study\n\nExclusion Criteria:\n\n* Have metastatic breast cancer or local recurrence\n* Have already received curative treatment (surgery, chemo, etc.) for the current breast cancer before joining the study\n* Are currently pregnant or breastfeeding\n* Have a history of another cancer within the past 5 years (except for non-melanoma skin cancer or in-situ cervical cancer)\n* Are unable to participate in the study due to mental, physical, or legal reasons (for example, under legal guardianship or imprisonment)",true,"FEMALE","18 Years",{"count":86,"type":87},3000,"ESTIMATED","5 Years","OBSERVATIONAL","This study, called PERSEVERE, examines how local treatment for early breast cancer affects people's health and daily lives over time.\n\nPeople who join the study will have early-stage breast cancer and receive treatment such as surgery and other therapies that are used before or after surgery. The study does not include people with late-stage (metastatic) breast cancer.\n\nResearchers want to learn about short- and long-term side effects that can happen during or after treatment. These may include tiredness, trouble sleeping, emotional distress, pain, or changes in heart or lung function. The study also looks at how these effects impact participants' quality of life.\n\nParticipants will be asked to complete surveys about how they feel. They will also have health checks, such as heart tests, lung function tests, and blood samples. Tissue samples from surgery will also be collected.\n\nThe goal is to understand better how different people respond to breast cancer treatment and find ways to support long-term recovery.",[92,93,94,95],"Breast Neoplasms","Quality of Life (QOL)","Toxicities","Breast Diseases",[92,97,98,99,100],"Treatment-Related Toxicities","Quality of Life","Patient-Reported Outcomes","Prospective Study","2025-09-08",{"date":103,"type":104},"2025-09-12","ACTUAL",{"date":106,"type":104},"2025-04-07",{"date":108,"type":87},"2028-12-31",{"name":72,"class":6},3]